



ADAP Advocacy Association

aaa+

Attn: Brandon M. Macsata, CEO

PO Box 15275

Washington, DC 20005

[info@adapadvocacyassociation.org](mailto:info@adapadvocacyassociation.org)

[www.adapadvocacyassociation.org](http://www.adapadvocacyassociation.org)

## ADAP Advocacy Association Announces HIV/HCV Co-Infection Summit

WASHINGTON, D.C. (March 19, 2013) – The [ADAP Advocacy Association](http://www.adapadvocacyassociation.org), also known as **aaa+**, today announced that it would host an “HIV/HCV Co-Infection ADAP Summit” in Las Vegas, NV on April 25-26, 2013. The summit, which is being held in partnership with the [Community Access National Network](http://www.cann.org) (CANN) and facilitated by [HealthHIV](http://www.healthhiv.org), will focus on the latest information on Hepatitis C drug development, patient assistance programs, and other updates about HIV/HCV co-infection, among other things.

“HIV/HCV Co-Infection is the sleeping giant that few people are talking about, but it will have major implications on our health care delivery systems...including already strained programs like ADAP,” said **Brandon M. Macsata**, CEO of the ADAP Advocacy Association. “Our goal is to assemble the experts in this field to learn from them and put together an action plan that will allow our community to be better prepared for this emerging crisis.”

The HIV/HCV Co-Infection ADAP Summit will convene a day-and-a-half roundtable, comprised of 30 representatives from various stakeholder groups. The roundtable will listen to several “big sky” presentations and engage in dialogue about them, as well as other ideas, all leading to the formulation of recommendations that will be shared with policy-makers.

The summit is open to the public, but only invited panelists will be participating on the roundtable – which will be facilitated by an independent moderator. To learn more about the summit online, go to <http://www.adapadvocacyassociation.org/events.html>.

“CANN has long been recognized for its commitment to promoting patient access to timely care and treatment, and we need to educate consumers, community partners, as well as congressional staff here in Washington, D.C. about the fastest growing public health epidemic since AIDS: HCV infection,” summarized **Bill Arnold**, President & CEO of the Community Access National Network. “We have learned many valuable lessons from the HIV/AIDS advocacy community over the last three decades, and CANN will now apply those lessons to ensuring access to effective HCV treatments.”

Potential areas of discussion include to identify funding shortfalls within ADAP, and bring to the forefront dialogue and a strategy to attain more funding for ADAP to treat co-infected clients; identify potential HCV rebate dollars available using ADAP rebate methodology; and facilitate ongoing dialogue between ADAP stakeholders, pharmaceutical industry and other applicable entities in order to collectively identify practical strategies to improve access to care for people co-infected with HIV/HCV.

To learn more about the HIV/HCV Co-Infection ADAP Summit, or the ADAP Advocacy Association, please contact Brandon M. Macsata by phone at (305) 519-4256 or email at [info@adapadvocacyassociation.org](mailto:info@adapadvocacyassociation.org).

#####